Deal covers production of HIV drANX-201 (Thiovir™).

Adventrx Pharmaceuticals entered into an agreement with Pharmatek Laboratories for the manufacturing of ANX-201 (Thiovir) capsules for clinical studies.

“Pharmatek is an experienced contract manufacturer and we are confident in their ability to produce reliable cGMP material for our clinical trials,” says Michele Yelmene, vp of regulatory affairs. “The drug supply they generate under this contract is expected to provide the company with inventory for our Phase I/II study in HIV, which we anticipate initiating later this year.”

ANX-201 is a member of a new class of reverse transcriptase inhibitors designed for oral delivery as a component of AZT-based highly active antiretroviral therapy. The product is a pyrophosphate analog that delivers both thiophosphonoformate and phosphonoformate (PFA, foscarnet).

Previous articleChromos and Pain Thearapeutics Okay Cell Line Engineering Agreement
Next articleGenVec Signs CRADA with the NIAID to Develop RSV Vaccines